Predictive Modeling of Mortality in Polymyositis/Dermatomyositis Patients with Interstitial Lung Disease Based on Combination of Serum Myositis-Specific Autoantibodies and Conventional Biomarkers

被引：0
|
作者：
Gono, Takahisa [1 ]
Masui, Kenichi [2 ]
Kawaguchi, Yasushi [3 ]
Ikeda, Kei [4 ]
Kawakami, Atsushi [5 ]
Tamura, Maasa [6 ]
Tanino, Yoshinori [7 ]
Nunokawa, Takahiro [8 ]
Kaneko, Yuko [9 ]
Sato, Shinji [10 ]
Asakawa, Katsuaki [11 ]
Nishina, Naoshi [9 ]
Kuwana, Masataka [1 ]
机构：
[1] Nippon Med Sch, Dept Allergy & Rheumatol, Grad Sch Med, Tokyo, Japan
[2] Natl Def Med Coll, Sch Med, Dept Anesthesiol, Tokorozawa, Saitama, Japan
[3] Tokyo Womens Med Univ, Inst Rheumatol, Tokyo, Japan
[4] Chiba Univ Hosp, Dept Allergy & Clin Immunol, Chiba, Japan
[5] Nagasaki Univ, Div Adv Prevent Med Sci, Dept Immunol & Rheumatol, Grad Sch Biomed Sci, Nagasaki, Japan
[6] Yokohama City Univ, Dept Stem Cell & Immune Regulat, Grad Sch Med, Yokohama, Kanagawa, Japan
[7] Fukushima Med Univ, Dept Pulm Med, Sch Med, Fukushima, Japan
[8] Tokyo Metropolitan Tama Med Ctr, Dept Rheumat Dis, Tokyo, Japan
[9] Keio Univ, Div Rheumatol, Dept Internal Med, Sch Med, Tokyo, Japan
[10] Tokai Univ, Dept Internal Med, Div Rheumatol, Sch Med, Isehara, Kanagawa, Japan
[11] Niigata Univ Med & Dent Hosp, Div Resp Med, Niigata, Japan
来源：
ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 47 条
  • [31] MYOSITIS-SPECIFIC AND ASSOCIETED ANTIBODIES, ESPECIALLY ANTI-ARS ANTIBODIES AND ANTI-RO52 ANTIBODY MAY PREDICT THE CHARACTERISTICS AND FIBROSING PROGRESS OF INTERSTITIAL LUNG DISEASE WITH DERMATOMYOSITIS / POLYMYOSITIS
    Nakashima, S.
    Nakaishi, H.
    Shimada, H.
    Wakiya, R.
    Kato, M.
    Miyagi, T.
    Sugihara, K.
    Mino, R.
    Mizusaki, M.
    Kameda, T.
    Dobashi, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 757 - 758
  • [32] Multiple Serum Cytokine and Chemokine Profiling to Identify Combinational Biomarkers Toward Patients of Polymyositis/Dermatomyositis Complicated with Rapidly Progressive Interstitial Lung Disease
    Shimizu, Toshimasa
    Koga, Tomohiro
    Horai, Yoshiro
    Fujikawa, Keita
    Endo, Yushiro
    Tsuji, Sousuke
    Takatani, Ayuko
    Umeda, Masataka
    Fukui, Shoichi
    Sumiyoshi, Remi
    Nishino, Ayako
    Kawashiri, Shinya
    Iwamoto, Naoki
    Igawa, Takashi
    Ichinose, Kunihiro
    Tamai, Mami
    Sakamoto, Noriho
    Nakamura, Hideki
    Origuchi, Tomoki
    Mukae, Hiroshi
    Kuwana, Masataka
    Kawakami, Atsushi
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [33] Interstitial lung disease and myositis-specific and associated autoantibodies: Clinical manifestations, survival and the performance of the new ATS/ERS criteria for interstitial pneumonia with autoimmune features (IPAF)
    Mejia, Mayra
    Herrera-Bringas, Denisse
    Perez-Roman, Diana I.
    Rivero, Hermes
    Mateos-Toledo, Heidegger
    Castorena-Garcia, Pedro
    Figueroa, Jose E.
    Rojas-Serrano, Jorge
    RESPIRATORY MEDICINE, 2017, 123 : 79 - 86
  • [34] Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease
    Ihn, H
    Asano, Y
    Kubo, M
    Yamane, K
    Jinnin, M
    Yazawa, N
    Fujimoto, M
    Tamaki, K
    RHEUMATOLOGY, 2002, 41 (11) : 1268 - 1272
  • [35] Serum Anti-Ars And Anti-Mda-5 Antibodies Are Useful Biomarkers For Predicting The Prognosis In Patients With Polymyositis/dermatomyositis-Associated Interstitial Lung Disease
    Hozumi, H.
    Fujisawa, T.
    Kono, M.
    Enomoto, N.
    Inui, N.
    Nakamura, Y.
    Suda, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [36] Quantification of Myositis-specific Autoantibodies in Idiopathic Inflammatory Myopathy-associated Interstitial Lung Disease Using the Luciferase Immunoprecipitation System (LIPS): Implications for Disease Severity and Treatment Response
    Huapaya, J. A.
    Burbelo, P.
    Pinal-Fernandez, I.
    Casal-Dominguez, M.
    Tian, X.
    Schiffenbauer, A.
    Rider, L.
    Suffredini, A. F.
    Mammen, A.
    Danoff, S. K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [37] A Predictive Model of Disease Outcome in Rituximab-Treated Myositis Patients Using Clinical Features, Autoantibodies, and Serum Biomarkers.
    Olazagasti, Jeannette
    Crowson, Cynthia S.
    Hein, Molly S.
    de Padilla, Consuelo Lopez
    Aggarwal, Rohit
    Oddis, Chester V.
    Reed, Ann M.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S405 - S406
  • [38] Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis
    So, Jacqueline
    So, Ho
    Wong, Victor Tak-Lung
    Ho, Roy
    Wu, Tsz Yuen
    Wong, Priscilla Ching-Han
    Tam, Lydia Ho-Pui
    Ho, Chi
    Lam, Tommy Tsz-On
    Chung, Yuen Kwan
    Li, Wai Ling
    To, Chi Hung
    Lau, Chak Sing
    Mok, Chi Chiu
    Tam, Lai-Shan
    RHEUMATOLOGY, 2022, 61 (11) : 4437 - 4444
  • [39] Predictors of Rapidly Progressive Interstitial Lung Disease and Mortality in Patients with Autoantibodies Against Melanoma Differentiation-Associated Protein 5 Dermatomyositis
    So, Jacqueline
    Tam, Lai-Shan
    Wong, Priscilla
    Tam, Lydia Ho-Pui
    Lam, Tsz On
    Mok, Chi Chiu
    To, Chi Hung
    Chung, Yuen Kwan
    Wong, Victor Tak Lung
    Wu, Tsz Yuen
    Ho, Roy
    Li, Wai Ling
    Ho, Chi
    So, Ho
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1384 - 1386
  • [40] Myositis autoantibodies in Korean patients with inflammatory myositis: Anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis
    Eun Ha Kang
    Ran Nakashima
    Tsuneyo Mimori
    Jinhyun Kim
    Yun Jong Lee
    Eun Bong Lee
    Yeong Wook Song
    BMC Musculoskeletal Disorders, 11
12345